Elanco Animal Health Inc
NYSE:ELAN

Watchlist Manager
Elanco Animal Health Inc Logo
Elanco Animal Health Inc
NYSE:ELAN
Watchlist
Price: 24.325 USD -1.72% Market Closed
Market Cap: $12.1B

Relative Value

The Relative Value of one ELAN stock under the Base Case scenario is 21.607 USD. Compared to the current market price of 24.325 USD, Elanco Animal Health Inc is Overvalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELAN Relative Value
Base Case
21.607 USD
Overvaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

ELAN Competitors Multiples
Elanco Animal Health Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Elanco Animal Health Inc
NYSE:ELAN
12.1B USD 2.6 336 17.1 64.5
US
Eli Lilly and Co
NYSE:LLY
948.8B USD 16 51.5 34.6 37.1
US
Johnson & Johnson
NYSE:JNJ
563B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
282B CHF 4.6 30 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.9B GBP 5.1 31.7 15.1 22.1
US
Merck & Co Inc
NYSE:MRK
288.1B USD 4.5 15.1 10.7 12.7
CH
Novartis AG
SIX:NOVN
225.6B CHF 5.2 20.2 12.7 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
98B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
US
Elanco Animal Health Inc
NYSE:ELAN
Average P/E: 54.5
336
20%
16.8
US
Eli Lilly and Co
NYSE:LLY
51.5
54%
1
US
Johnson & Johnson
NYSE:JNJ
21
6%
3.5
CH
Roche Holding AG
SIX:ROG
30
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
38%
0.8
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
CH
Novartis AG
SIX:NOVN
20.2
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Elanco Animal Health Inc
NYSE:ELAN
Average EV/EBITDA: 43.4
17.1
6%
2.8
US
Eli Lilly and Co
NYSE:LLY
34.6
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Elanco Animal Health Inc
NYSE:ELAN
Average EV/EBIT: 95.6
64.5
51%
1.3
US
Eli Lilly and Co
NYSE:LLY
37.1
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.9
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
US
Merck & Co Inc
NYSE:MRK
12.7
8%
1.6
CH
Novartis AG
SIX:NOVN
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3